

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2017/141104 A8

(43) International Publication Date
24 August 2017 (24.08.2017)

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61P 9/00* (2006.01)
A61K 45/06 (2006.01) *A61P 31/12* (2006.01)
A61K 31/485 (2006.01) *A61P 37/00* (2006.01)
A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/IB2017/000124

(88) Date of publication of the international search report:

02 November 2017 (02.11.2017)

(22) International Filing Date:

17 February 2017 (17.02.2017)

(48) Date of publication of this corrected version:

22 March 2018 (22.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/296,759 18 February 2016 (18.02.2016) US

(71) Applicant: IMMUNE THERAPEUTICS, INC. [US/US];
37 N. Orange Avenue, Orlando, FL 32801 (US).

(72) Inventors: PLOTNIKOFF, Nicholas; 25 Harbor Road,
Ocean City, NJ 08226 (US). **SHAN, Fengping;** Room 1-5
Building 55-17, Wuxi St., Shenhe District, Shenyang Liaon-
ing Province (CN). **GRIFFIN, Noreen;** 250 Alexander
PLace, Winter Park, FL 32789 (US).

(74) Agent: BROWN, Michael J.; Michael J. Brown Law Of-
fice LLC, 354 Eisenhower Parkway, Plaza I, 2nd Floor,
Suite 2025, Livingston, NJ 07039 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHOD FOR INDUCING A SUSTAINED IMMUNE RESPONSE

(57) Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about .01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about .01 and about 10 mg of naltrexone.



WO 2017/141104 A8